Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses what is known about the pathobiology of frontal fibrosing alopecia and reports no new clinical findings, highlighting potential environmental and genetic factors in disease pathogenesis.

This study found that oral tofacitinib led to clinically significant improvement in alopecia areata severity scores among pre-adolescents, though results varied and further evaluation in clinical trials is needed.

This review discusses the use of tofacitinib as a treatment for plaque psoriasis, highlighting its efficacy and safety in clinical trials, but notes unresolved questions regarding long-term safety.

This study presents a validated questionnaire, the FFA-QLI, which effectively assesses and differentiates the quality of life impact among patients with frontal fibrosing alopecia, showing greater sensitivity in identifying severe cases than the DLQI.

This study assessed oral tofacitinib's effectiveness and safety in treating different forms of alopecia, finding that 80% of patients experienced hair regrowth improvements over 24 weeks with no adverse events reported.

This study from North-East India analyzed 21 cases of frontal fibrosing alopecia, noting a high prevalence in post-menopausal women and distinct histological features such as perifollicular lymphocytic infiltrate and hydropic degeneration.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

The document concludes that individualized Facial Feminization Surgery plans and comprehensive care are crucial for successful outcomes.

This dissertation demonstrates that FERONIA regulates essential plant functions such as RAC/ROP signaling, pollen tube reception, cell wall integrity, and sugar signaling as a cell surface receptor kinase.

This article reports a case of frontal fibrosing alopecia in its early inflammatory stage that responded positively to intralesional steroid treatment.

Tufted folliculitis is common in patients with folliculitis decalvans.

This study found that oral isotretinoin significantly reduced symptoms in nearly 90% of patients with frontal fibrosing alopecia, affecting both facial papules and hair loss.

This research discusses Fahr syndrome, highlighting its association with abnormal brain calcifications and varied clinical symptoms in young to middle-aged adults. Diagnosis involves specific criteria and CT scans, but no specific treatment exists; therapy focuses on managing symptoms and underlying conditions.

This review discusses the potential causes and treatments for frontal fibrosing alopecia but reports no new clinical findings, highlighting the need for further research to understand its pathogenesis and develop validated treatments.

This study reports that a 21-year-old male with alopecia totalis responded positively to the JAK inhibitor tofacitinib, achieving complete hair regrowth after six months of treatment without significant side effects, though further research is needed to evaluate long-term efficacy.

In this study, researchers developed topical tofacitinib-loaded cationic lipid nanoparticles, which improved absorption and targeted hair follicles in an ex vivo pig ear model, showing promise in treating alopecia areata by reducing symptoms through the JAK/STAT pathway.

This review discusses frontal fibrosing alopecia in males and reports no new clinical results, indicating a broader demographic affected by this inflammatory disorder beyond postmenopausal women.

In this study, 2′‐Fucosyllactose (2′‐FL) administration significantly reduced hair loss and increased hair length and thickness in a testosterone-induced androgenic alopecia mouse model, suggesting potential as a therapeutic agent for AGA.

This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.

Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.

In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.

This case report described a 24-year-old with alopecia totalis who saw full scalp hair regrowth by the 9th month while using oral tofacitinib, which was well-tolerated and did not show serious adverse effects. Longer-term studies are needed to confirm its overall effectiveness for alopecia totalis.

This study investigated immune dysregulation in individuals with Down syndrome and found that treatment with the JAK inhibitor tofacitinib improved skin conditions like alopecia areata and reduced autoimmune markers without severe side effects. Additional research is necessary to understand its broader impacts.

This study suggests that infrared thermography may be a useful noninvasive tool for diagnosing active phases of frontal fibrosing alopecia when combined with dermoscopy.

In this study, facial feminization surgeries were found to be effective and generally safe, significantly enhancing feminine appearance in patients, with minimal major complications reported.

Finasteride significantly reduced tics and obsessive-compulsive symptoms in Tourette syndrome patients.

This report describes two unusual cases of frontal fibrosing alopecia in men, highlighting potential vaccine-related immune triggers and genetic factors, especially regarding the pronounced facial papular phenotype observed.

This study found that topical tacalcitol improved roughness and scaling in erythromelanosis follicularis faciei et colli, although it was less effective for facial erythema.

This study found that trichoscopy is an effective noninvasive technique for diagnosing frontal fibrosing alopecia, confirming its valuable role alongside traditional histopathological examination.